We therefore compared miR-29b levels in patients with different tumor localizations (Figure 2A), with lower or higher Ki-67 rates (Figure 2B), different histological tumor grading (Figure 2C), functional or non-functional disease (Figure 2D), as well as positive or negative somatostatin receptor (SSR) expression status (Figure 2E). This evidence concerns the gene MKI67 and neoplasm.